Improvement in clinical markers in CF patients using a reduced glutathione regimen: an uncontrolled, observational study.

Visca A, Bishop CT, Hilton SC, Hudson VM

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society21 May 2008Cited by 24 (Europe PMC)

PMID18499536DOI10.1016/j.jcf.2008.03.006PepBankPUB-18499536

Source link PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanObservational studyEfficacy outcome
In cystic fibrosis, a glutathione regimen was linked to a mean weight percentile increase of 8.6 points from baseline.
In plain wordsIn cystic fibrosis, a glutathione regimen was linked to an 8.6 point weight percentile increase from baseline.
Peptide
Glutathione
Outcome
IncreaseWeight percentile
Study
n = 13
Outcome group
Body weight · Metabolic and weight
Studied dose
66-148 mg/kg/day in divided doses · oral and inhaled · 5.5 monthsAs given in this study (human).
Measurements
Weight percentile change
8.6 points
from baseline
P value for weight percentile change from baseline
< 0.001
glutathione regimen, posttreatment versus baseline
Source sentences
Summary
average weight percentile (N=13) increased 8.6 points (p<0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
We followed 13 patients (age range 1-27 years) with cystic fibrosis who were using a regimen of reduced glutathione (GSH), including oral glutathione and inhaled buffered glutathione in an uncontrolled, observational study.
Summary · context
Dosage ranged from 66-148 mg/kg/day in divided doses, and the term examined was the initial 5.5 months of GSH use (45 days of incrementally adjusted dose, plus 4 months of use at full dosage).
Report a problemFND-1849953602
02HumanObservational studyEfficacy outcome
In cystic fibrosis, 12 of 13 patients improved in weight percentile during use of the glutathione regimen.
In plain wordsIn cystic fibrosis, 12 of 13 patients improved in weight percentile during use of the glutathione regimen.
Peptide
Glutathione
Outcome
IncreasePatients with improved weight percentile
Study
n = 13
Outcome group
Body weight · Metabolic and weight
Studied dose
66-148 mg/kg/day in divided doses · oral and inhaled · 5.5 monthsAs given in this study (human).
Measurements
Patients with improved weight percentile
12 patients
of 13
Source sentences
Summary
All patients improved in FEV1 and BMI, if measured in their case; 12 of 13 patients improved in weight percentile.
2 context sentences(design, population, supporting numbers)
Summary · context
We followed 13 patients (age range 1-27 years) with cystic fibrosis who were using a regimen of reduced glutathione (GSH), including oral glutathione and inhaled buffered glutathione in an uncontrolled, observational study.
Summary · context
Dosage ranged from 66-148 mg/kg/day in divided doses, and the term examined was the initial 5.5 months of GSH use (45 days of incrementally adjusted dose, plus 4 months of use at full dosage).
Report a problemFND-1849953606
03HumanObservational studyEfficacy outcome
In cystic fibrosis, a glutathione regimen was linked to a mean BMI percentile increase of 1.22 points from baseline.
In plain wordsIn cystic fibrosis, a glutathione regimen was linked to a 1.22 point BMI percentile increase from baseline.
Peptide
Glutathione
Outcome
IncreaseBMI percentile
Study
n = 11
Outcome group
Body weight · Metabolic and weight
Studied dose
66-148 mg/kg/day in divided doses · oral and inhaled · 5.5 monthsAs given in this study (human).
Measurements
BMI percentile change
1.22 points
from baseline
P value for BMI percentile change from baseline
< 0.001
glutathione regimen, posttreatment versus baseline
Source sentences
Summary
BMI percentile (N=11) improved on average 1.22 points (p<0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We followed 13 patients (age range 1-27 years) with cystic fibrosis who were using a regimen of reduced glutathione (GSH), including oral glutathione and inhaled buffered glutathione in an uncontrolled, observational study.
Summary · context
Dosage ranged from 66-148 mg/kg/day in divided doses, and the term examined was the initial 5.5 months of GSH use (45 days of incrementally adjusted dose, plus 4 months of use at full dosage).
Report a problemFND-1849953603
04HumanObservational studyEfficacy outcome
In cystic fibrosis, all patients with measured BMI improved during use of the glutathione regimen.
In plain wordsIn cystic fibrosis, all patients with measured BMI improved during use of the glutathione regimen.
Peptide
Glutathione
Outcome
IncreasePatients with improved BMI
Study
n = 11
Outcome group
Body weight · Metabolic and weight
Studied dose
66-148 mg/kg/day in divided doses · oral and inhaled · 5.5 monthsAs given in this study (human).
Source sentences
Summary
All patients improved in FEV1 and BMI, if measured in their case; 12 of 13 patients improved in weight percentile.
2 context sentences(design, population, supporting numbers)
Summary · context
We followed 13 patients (age range 1-27 years) with cystic fibrosis who were using a regimen of reduced glutathione (GSH), including oral glutathione and inhaled buffered glutathione in an uncontrolled, observational study.
Summary · context
Dosage ranged from 66-148 mg/kg/day in divided doses, and the term examined was the initial 5.5 months of GSH use (45 days of incrementally adjusted dose, plus 4 months of use at full dosage).
Report a problemFND-1849953605
05HumanObservational studyEfficacy outcome
In cystic fibrosis, a glutathione regimen was linked to a decline in positive bacterial sputum cultures from 13 to 5.
In plain wordsIn cystic fibrosis, a glutathione regimen was linked to fewer positive bacterial sputum cultures than at baseline.
Peptide
Glutathione
Outcome
DecreasePositive bacterial sputum cultures
Study
n = 11
Outcome group
Infection and antimicrobial activity · Infection
Studied dose
66-148 mg/kg/day in divided doses · oral and inhaled · 5.5 monthsAs given in this study (human).
Measurements
Positive cultures
13 cultures
baseline
Positive cultures
5 cultures
after treatment
P value for positive bacterial sputum cultures change from baseline
< 0.03
glutathione regimen, posttreatment versus baseline
Source sentences
Summary
Positive sputum cultures of bacteria in 11 patients declined from 13 to 5 (p<0.03)
2 context sentences(design, population, supporting numbers)
Summary · context
We followed 13 patients (age range 1-27 years) with cystic fibrosis who were using a regimen of reduced glutathione (GSH), including oral glutathione and inhaled buffered glutathione in an uncontrolled, observational study.
Summary · context
Dosage ranged from 66-148 mg/kg/day in divided doses, and the term examined was the initial 5.5 months of GSH use (45 days of incrementally adjusted dose, plus 4 months of use at full dosage).
Report a problemFND-1849953607
06HumanObservational studyEfficacy outcome
In cystic fibrosis, a glutathione regimen was linked to a mean FEV1 percent predicted increase of 5.8 percentage points from baseline.
In plain wordsIn cystic fibrosis, a glutathione regimen was linked to a 5.8 percentage point lung function increase from baseline.
Peptide
Glutathione
Outcome
IncreaseFEV1 percent predicted
Study
n = 10
Outcome group
Respiratory function · Respiratory
Studied dose
66-148 mg/kg/day in divided doses · oral and inhaled · 5.5 monthsAs given in this study (human).
Measurements
FEV1 percent predicted change
5.8 percentage points
from baseline
P value for FEV1 percent predicted change from baseline
< 0.0001
glutathione regimen, posttreatment versus baseline
Source sentences
Summary
Significant improvement in the following clinical parameters was observed: average improvement in FEV1 percent predicted (N=10) was 5.8 percentage points (p<0.0001)
2 context sentences(design, population, supporting numbers)
Summary · context
We followed 13 patients (age range 1-27 years) with cystic fibrosis who were using a regimen of reduced glutathione (GSH), including oral glutathione and inhaled buffered glutathione in an uncontrolled, observational study.
Summary · context
Dosage ranged from 66-148 mg/kg/day in divided doses, and the term examined was the initial 5.5 months of GSH use (45 days of incrementally adjusted dose, plus 4 months of use at full dosage).
Report a problemFND-1849953601
07HumanObservational studyEfficacy outcome
In cystic fibrosis, all patients with measured FEV1 improved during use of the glutathione regimen.
In plain wordsIn cystic fibrosis, all patients with measured lung function improved during use of the glutathione regimen.
Peptide
Glutathione
Outcome
IncreasePatients with improved FEV1
Study
n = 10
Outcome group
Respiratory function · Respiratory
Studied dose
66-148 mg/kg/day in divided doses · oral and inhaled · 5.5 monthsAs given in this study (human).
Source sentences
Summary
All patients improved in FEV1 and BMI, if measured in their case; 12 of 13 patients improved in weight percentile.
2 context sentences(design, population, supporting numbers)
Summary · context
We followed 13 patients (age range 1-27 years) with cystic fibrosis who were using a regimen of reduced glutathione (GSH), including oral glutathione and inhaled buffered glutathione in an uncontrolled, observational study.
Summary · context
Dosage ranged from 66-148 mg/kg/day in divided doses, and the term examined was the initial 5.5 months of GSH use (45 days of incrementally adjusted dose, plus 4 months of use at full dosage).
Report a problemFND-1849953604
08HumanObservational studyEfficacy outcome
In cystic fibrosis, Pseudomonas aeruginosa sputum cultures became negative in 4 of 5 previously positive patients during glutathione regimen use.
In plain wordsIn cystic fibrosis, Pseudomonas sputum cultures became negative in 4 of 5 previously positive patients during glutathione regimen use.
Peptide
Glutathione
Outcome
DecreasePseudomonas aeruginosa culture conversion
Study
n = 5
Outcome group
Infection and antimicrobial activity · Infection
Studied dose
66-148 mg/kg/day in divided doses · oral and inhaled · 5.5 monthsAs given in this study (human).
Measurements
Patients with negative Pseudomonas cultures
4 patients
of 5 previously positive
Source sentences
Summary
with sputum cultures of Pseudomonas aeruginosa becoming negative in 4 of 5 patients previously culturing PA
2 context sentences(design, population, supporting numbers)
Summary · context
We followed 13 patients (age range 1-27 years) with cystic fibrosis who were using a regimen of reduced glutathione (GSH), including oral glutathione and inhaled buffered glutathione in an uncontrolled, observational study.
Summary · context
Dosage ranged from 66-148 mg/kg/day in divided doses, and the term examined was the initial 5.5 months of GSH use (45 days of incrementally adjusted dose, plus 4 months of use at full dosage).
Report a problemFND-1849953608
09HumanObservational studyEfficacy outcome
In cystic fibrosis, two of three chronically Pseudomonas-infected patients had negative sputum cultures during glutathione regimen use.
In plain wordsIn cystic fibrosis, two of three chronically Pseudomonas-infected patients had negative sputum cultures during glutathione regimen use.
Peptide
Glutathione
Outcome
DecreaseChronic Pseudomonas culture conversion
Study
n = 3
Outcome group
Infection and antimicrobial activity · Infection
Studied dose
66-148 mg/kg/day in divided doses · oral and inhaled · 5.5 monthsAs given in this study (human).
Measurements
Chronically Pseudomonas-infected patients with negative sputum cultures
2 patients
of three chronically infected patients, during glutathione regimen use
Source sentences
Summary
with sputum cultures of Pseudomonas aeruginosa becoming negative in 4 of 5 patients previously culturing PA, including two of three patients chronically infected with PA as determined by antibody status.
2 context sentences(design, population, supporting numbers)
Summary · context
We followed 13 patients (age range 1-27 years) with cystic fibrosis who were using a regimen of reduced glutathione (GSH), including oral glutathione and inhaled buffered glutathione in an uncontrolled, observational study.
Summary · context
Dosage ranged from 66-148 mg/kg/day in divided doses, and the term examined was the initial 5.5 months of GSH use (45 days of incrementally adjusted dose, plus 4 months of use at full dosage).
Report a problemFND-1849953609

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.